FDA
-
-
-
-
-
-
-
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology
-
-
-
-
-
-
-
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery
-
-
-
-
-
-
-
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
-
-
-
-
-
-
-
Pulse Biosciences, Inc. (PLSE) Files 510(k) Submission with U.S. FDA for its CellFX nsPFA™ Cardiac Clamp
-
-
-
-
-
-
-
Pulse Biosciences Clarifies Details of Recent S-3 Filing
-
-
-
-
-
-
-
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

